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Hepatitis E virus (HEV) is an important but extremely understudied human pathogen, and the mechanisms
of HEV replication and pathogenesis are largely unknown. We previously identified an attenuated genotype 3
HEV mutant (pSHEV-1) containing three unique amino acid mutations (F51L, T59A, and S390L) in the capsid
protein. To determine the role of each of these mutations, we constructed three HEV single mutants (rF51L,
rT59A, and rS390L) which were all found to be replication competent in Huh7 liver cells. To determine the
pathogenicities of the mutants, we utilized the specific-pathogen-free (SPF) pig model for HEV and a unique
inoculation procedure that bypasses the need for propagating infectious HEV in vitro. A total of 60 pigs were
intrahepatically inoculated, via an ultrasound-guided technique, with in vitro-transcribed full-length capped
RNA transcripts from the infectious clones of each single mutant, the pSHEV-1 triple mutant, wild-type
pSHEV-3, or phosphate-buffered saline (PBS) buffer (n  10). The results showed that the F51L mutation
partially contributed to virus attenuation, whereas the T59A and S390L mutations resulted in more drastic
attenuation of HEV in pigs, as evidenced by a significantly lower incidence of viremia, a delayed appearance
and shorter duration of fecal virus shedding and viremia, and lower viral loads in liver, bile, and intestinal
content collected at three different necropsy times. The results indicate that the three mutations in the capsid
protein collectively contribute to HEV attenuation. This study has important implications for developing a
modified live-attenuated vaccine against HEV.
Hepatitis E virus (HEV) is a major cause of enterically
transmitted acute hepatitis in many developing countries in
Asia, the Middle East, and Africa and in Mexico (2, 13, 40–42,
49), although the disease has also been reported in many in-
dustrialized countries, including the United States (53). HEV
is transmitted primarily by the fecal-oral route through con-
taminated drinking water or food. The disease generally affects
young adults and has a mortality rate of less than 1% in the
general population, although a significantly higher rate of mor-
tality, up to 30%, has been reported in infected pregnant
women (47). HEV is a small nonenveloped virus, and its ge-
nome is a single-strand, positive-sense RNA molecule of ap-
proximately 7.2 kb in size. Currently, HEV is classified in the
genus Hepevirus of the family Hepeviridae (9).
The genomic RNA of HEV contains a short 5 noncoding
region (NCR), three open reading frames (ORF1, -2, and -3),
and a 3 NCR (22). A cap structure has been identified at the
5 end of the viral genome and is required for efficient virus
replication in vivo (14). The ORF2 and ORF3 proteins are
translated from a bicistronic subgenomic mRNA (18, 25).
ORF1 encodes a nonstructural protein with multiple func-
tional domains, including methyltransferase, papain-like pro-
tease, helicase, and RNA-dependent RNA polymerase
(RdRp) (29). It remains unclear whether the ORF1 polypro-
tein functions as a single protein with multiple functional do-
mains or as individually cleaved smaller proteins. Thus far, the
functions of the helicase and methyltransferase domains in
ORF1 have been experimentally confirmed (26–28, 36). A pro-
line-rich hypervariable region in ORF1 was found to be dis-
pensable for HEV replication both in vitro and in vivo (51),
although the biological significance of this region remains un-
known. ORF2, located at the 3 end of the genome, encodes
the viral capsid protein, which contains a signal sequence and
three glycosylation sites (13). The ORF2 capsid protein is
involved in virion assembly, immunogenicity, and host cell re-
ceptor binding (23, 30, 34, 39, 55). The capsid protein is
cleaved between amino acids (aa) 111 and 112, resulting in a
55-kDa capsid protein without the signal sequence that can still
form virus-like particles (VLPs) (13). It has been demonstrated
that mutations within the glycosylation sites prevent the for-
mation of infectious virus particles (19). It has been reported
that homodimers of the truncated HEV capsid proteins, E2
(amino acid residues 394 to 606) and p239 (amino acid resi-
dues 368 to 606), contain dominant antigenic determinants and
that rhesus monkeys immunized with the homodimers are pro-
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tected against HEV infection (31). The ORF3 gene overlaps
with ORF2 (18, 25) and encodes a small multifunctional pro-
tein (1, 5, 6, 11, 12, 18, 46, 57, 58, 61–63, 68). ORF3 is trans-
lated from the third in-frame AUG codon in the ORF1/ORF2
intergenic region and encodes a protein that is essential for
virus infectivity in vivo (25), although the expression of ORF3
protein is not required for virus replication, virion assembly, or
infection in vitro (10, 11). The N terminus of ORF3 binds to
HEV RNA and forms a complex with the capsid protein.
The C terminus of the ORF3 protein may be involved in
virion egress from infected cells and virion morphogenesis
(12, 58, 68).
At least four major genotypes of HEV have been identified
in mammalian species (40, 41). Genotype 1 and 2 strains are
restricted to humans (43), whereas genotype 3 and 4 strains
have been identified in humans, pigs, and several other animal
species and are known to be zoonotic (3, 33, 37, 40, 41, 44, 45,
70, 71). The mechanisms of HEV pathogenesis and replication
are still not well understood. In a previous study, we identified
three mutations (F51L, T59A, and S390L) in the capsid pro-
tein of a strain of genotype 3 HEV (pSHEV-1) (24). These
three mutations are unique to pSHEV-1, as the residues F51,
T59, and S390 are conserved among all other known mamma-
lian HEV strains (24). In a pilot study with only two pigs, we
found that both pigs infected with pSHEV-1 had delayed se-
roconversion and delayed fecal virus shedding with undetect-
able viremia (24), thus suggesting a potential attenuation.
Therefore, the objectives of this study were to determine if all
three mutations contribute to HEV attenuation in a pathogenicity
study with a large number of specific-pathogen-free (SPF) pigs
and to dissect the role of each of these three amino acid muta-
tions in virus attenuation. Three HEV single mutants (rF51L,
rT59A, and rS390L) were constructed, their viabilities in Huh7
liver cells were tested, and subsequently the pathogenicity of each
mutant was compared to those of the wild-type pSHEV-3 virus
and the other mutants in a unique SPF pig model for HEV.
MATERIALS AND METHODS
Cells and infectious cDNA clones. A subclone of a human hepatoma cell line
(Huh7), originally isolated in Japan, was maintained in Dulbecco’s modified
Eagle medium (DMEM) (GIBCO) supplemented with 10% fetal bovine serum
under a 5% CO2 atmosphere at 37°C. Transfected cells were maintained under
the same conditions except at 34.5°C. The infectious cDNA clone pSHEV-3 from
a strain of genotype 3 HEV and its derived mutant infectious clone pSHEV-1
containing the three capsid mutations (F51L, T59A, and S390L) were described
in a previous study (24).
Construction of HEV mutants. The wild-type genotype 3 HEV pSHEV-3 was
used as the backbone for the construction of three single mutants (rF51L, rT59A,
and rS390L) by site-directed mutagenesis. Briefly, a partial fragment of ORF2
was subcloned into pCR2.1 vector (Invitrogen) and subsequently used to gener-
ate three single-amino-acid mutants. Overlapping primers were designed based
on the genomic sequence of pSHEV-3, each containing the desired nucleotide
change (underlined): for mutant rF51L, forward primer 51F (5-GTTGATTCT
CAGCCCCTCGCC-3) and reverse primer 51R (5-GGCGAGGGGCTGAGA
ATCAA-3); for mutant rT59A, forward primer 59F (5-CTATATTCATCCAG
CCAAC-3) and reverse primer 59R (5-GTTGGCTGGATGAATATAG-3);
and for mutant rS390L, forward primer 390F (5-GACAGAATTGATTTCGTT
GGCC-3) and reverse primer 390R (5-CGGCCAACGAAATCAATTCTGT-
3). Mutagenic primers were used in combination with the vector pCR2.1-specific
primers M13F (5-GTAAAACGACGGCCAG-3) and M13R (5-CAGGAAA
CAGCTATGAC-3) to generate two overlapping PCR products, which were
subsequently assembled into a final product of 1,463 bp by overlap extension
PCR. Each PCR product was gel purified, digested with AvrII and NdeI, and
then cloned back into the corresponding region of the pSHEV-3 infectious clone
to produce each of the three full-length single HEV mutants, rF51L, rT59A, and
rS390L. The entire ORF2 capsid gene for each mutant was sequenced to verify
the presence of the introduced mutations and the absence of other, unwanted
mutations.
In vitro RNA transcription. To generate full-length capped RNA transcripts
for in vitro viability studies, the wild-type pSHEV-3 infectious cDNA clone and
the three single mutant clones rF51L, rT59A, and rS390L were each linearized
with XbaI. Linearized plasmids were extracted with phenol-chloroform, followed
by ethanol precipitation. Capped RNA transcripts were synthesized by using a T7
riboprobe in vitro transcription system (Promega) as previously described (11).
Each reaction was performed in a final volume of 25 l containing 2.5 g of
linearized cDNA template, 5 l of 5 transcription buffer, 2.5 l of 10 mM
dithiothreitol, 1 l of 40 U/ml RNasin, 2.5 l of nucleoside triphosphates (5 mM
each ATP, CTP, and UTP and 0.5 mM GTP), 2.5 l of 5 mM m7(3-O-methyl)-
G(5)ppp(5)G (Ambion), and 1 l of 20-U/ml T7 polymerase. The reaction
mixture was incubated for 1.5 h at 37°C. To evaluate the integrity and quantity
of the RNA transcripts, a 2-l aliquot of the transcription reaction mixture was
analyzed in a 1% agarose gel. Transcription mixtures were cooled on ice and
directly used for in vitro transfection of Huh7 cells to determine the replication
competency of the wild-type and mutant viruses.
For the study of pathogenicity in pigs, capped RNA transcripts were synthe-
sized using the mMessage mMachine T7 kit (Ambion) as described previously
(24). Transcription reactions were performed for the wild-type pSHEV-3, the
triple mutant pSHEV-1, and each of the three single mutant (rF51L, rT59A, and
rS390L) infectious clones in a 200-l reaction mixture containing 10 g of
linearized DNA plasmid, 20 l of 10 buffer, 100 l of 2 nucleoside triphos-
phate-Cap, 20 l of enzyme mix, and an additional 10 l of 30 mM GTP. After
1.5 h of incubation at 37°C, the RNA transcripts for each clone were pooled. The
integrity of the RNA transcripts was determined by gel electrophoresis in a 1%
agarose gel and their concentration measured with a NanoDrop DN-1000 in-
strument (Thermo Scientific). The capped RNA transcripts for each clone were
diluted with 3 volumes of cold RNase-DNase-proteinase-free phosphate-buff-
ered saline (PBS) (6 ml), divided into aliquots of 0.8 ml, immediately frozen on
dry ice, and used for direct intrahepatic inoculation of pigs the next day.
In vitro transfection and immunofluorescence assay (IFA). Huh7 cells were
transfected with similar amounts of full-length capped RNA transcripts from the
wild-type pSHEV-3 clone and each of the three single mutant clones rF51L,
rT59A, and rS390L in order to determine their replication competencies in vitro.
Monolayers of Huh7 cells were washed with Opti-MEM (Gibco) and transfected
with RNA transcripts with DMRIE-C (Invitrogen) as previously described (11).
Briefly, 25 l of the transcription mixture was diluted in 1 ml of Opti-MEM
containing 20 l of DMRIE-C reagent, and the mixture was added to a T25 flask
containing cells at 40 to 50% confluence. After incubation for 5 h at 34.5°C, the
transfection mixture was replaced with fresh growth medium supplemented with
10% fetal bovine serum, and the cultures were maintained at 34.5°C. On day 3
posttransfection, cells were trypsinized, plated in eight-well LabTek chamber
slides, and grown for an additional 3 days at 34.5°C. On day 6 posttransfection,
cells were fixed with acetone for 2 min, washed with PBS, and incubated at room
temperature for 30 min with a chimpanzee 1313 anti-HEV antiserum diluted
1:200 in a dilution buffer (0.5% bovine serum albumin [BSA], 0.5% milk, and
0.1% Triton X-100 in PBS). This chimpanzee anti-HEV antiserum was used
because it has a very high titer and was shown to be specific for the HEV ORF2
protein (14, 24). Cells were washed with PBS and incubated with 1:2,000-diluted
Alexa Fluor 488-conjugated goat anti-human IgG (Molecular Probes) for 30 min
at room temperature. Slides were washed with PBS, covered with Vectashield
fluorescent mounting medium (Vector Laboratories), and viewed under a fluo-
rescence microscope (Nikon Eclipse TE300).
Experimental design for pathogenicity study of the HEV mutants in SPF pigs.
The study protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) of Iowa State University (approval number 3-09-6703-S) as
well as by the IACUC of Virginia Polytechnic Institute and State University
(approval number 09-058-CVM). Sixty 3-week-old, specific-pathogen-free (SPF)
pigs were distributed randomly into six groups (groups A, B, C, D, E, and F) of
10 pigs each. Each group of pigs was housed separately in a biosafety level 2
(BSL2) facility. Prior to inoculation, all pigs tested negative for IgG anti-HEV
antibodies by an enzyme-linked immunosorbent assay (ELISA) (43–45). Capped
RNA transcripts were thawed and immediately inoculated by an ultrasound-
guided percutaneous intrahepatic injection procedure into four different sites of
the liver, with approximately 200 l of capped RNA transcripts per injection site.
Group A pigs were each injected intrahepatically with 0.8 ml of the capped RNA
transcripts from the wild-type pSHEV-3 clone and served as positive controls.
Pigs in groups B, C, and D were each injected intrahepatically with 0.8 ml of the
capped RNA transcripts from the HEV single mutant clones rF51L, rT59A, and
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rS390L, respectively. Group E pigs were each similarly injected with 0.8 ml of the
capped RNA transcripts from the triple mutant pSHEV-1 clone, and pigs in
group F were injected with PBS and served as negative controls. All pigs were
monitored daily for clinical signs of disease for a total of 8 weeks.
Serum samples and fecal swabs were collected prior to inoculation and weekly
thereafter from each pig and were tested for the presence and the amount of
HEV RNA. Serum samples were also tested for the presence of HEV antibodies.
In order to evaluate and compare the levels of replication of different HEV
mutants during the acute stages of infection, three pigs from each group were
necropsied at 21 and 28 days postinoculation (dpi), and the remaining four pigs
from each group were necropsied at 56 dpi. The viral loads (amounts of HEV
RNA) in the bile, liver tissues, and intestinal content collected at each necropsy
were quantified as well.
Serology. Weekly serum samples were tested for IgG anti-HEV by an ELISA
essentially as described previously (43–45). Briefly, a truncated recombinant
ORF2 capsid protein containing the HEV immunodominant region from aa 452
to 617 (GenWay Biotech Inc., San Diego, CA) was used as the antigen. Horse-
radish peroxidase (HRP)-conjugated goat anti-swine IgG (Sigma) was used as
the secondary antibody. Preimmune and hyperimmune anti-HEV-positive swine
sera were included as negative and positive controls, respectively.
RNA extraction, cDNA synthesis, and nested reverse transcription-PCR (RT-
PCR). Samples of liver tissues (500 mg) collected at each necropsy were homog-
enized in 10% (wt/vol) sterile PBS. Homogenates were centrifuged at 3,000 rpm
(Eppendorf centrifuge 5810) at 4°C for 15 min, and supernatants were used for
the detection and quantification of HEV RNA. Intestinal content collected
during each necropsy and weekly fecal swab materials from each pig were
resuspended in PBS to make a 10% fecal suspension. Total RNA was extracted
from 200 l of serum, fecal suspension, liver homogenate, bile, and intestinal
content samples using TRIzol reagent (GIBCO-BRL) and was resuspended in 30
l of DNase-, RNase-, and proteinase-free water (Eppendorf Inc.). Synthesis of
cDNA was performed for 60 min at 42°C using 1 l of 10 M R1 reverse primer
(5-CTACAGAGCGCCAGCCTTGATTGC-3), 0.25 l (20 U/l) of Super-
script II reverse transcriptase (Invitrogen), 1 l of 0.1 M dithiothreitol, 4 l of 5
RT buffer, 0.5 l (40 U/l) of RNase inhibitor (Promega), and 1 l of 10 mM
deoxynucleoside triphosphates (dNTPs).
A nested RT-PCR was used to detect HEV RNA in serum, fecal, bile, and
liver samples. Primers used for RT-PCR were designed within the ORF2 capsid
gene. Briefly, 5 l of cDNA was amplified in a 50-l volume in a nested PCR with
AmpliTaq gold DNA polymerase (Applied Biosystems). The first round of PCR
was performed using F1 (forward, 5-AGCTCCTGTACCTGATGTTGACTC-
3) and R1 (reverse, 5-CTACAGAGCGCCAGCCTTGATTGC-3) primers to
produce an expected fragment of 404 bp. A second round of PCR was carried out
in the presence of the F2 (5-GCTCACGTCATCTGTCGCTGCTGG-3) and
R2 (5-GGGCTGAACCAAAATCCTGACATC-3) primers to generate a prod-
uct of 266 bp, using 5 l of the first-round PCR products as the template. The
PCR parameters for both rounds included an initial incubation at 95°C for 9 min,
followed by 40 cycles of denaturation at 94°C for 1 min, annealing at 52°C for 1
min, and extension at 72°C for 1.5 min, with a final incubation at 72°C for 7 min.
Amplified PCR products were analyzed by gel electrophoresis.
Quantification of HEV RNA by qRT-PCR. All serum, liver tissue homogenate,
bile, and intestinal content samples that were tested positive by the nested
RT-PCR assay were retested by quantitative RT-PCR (qRT-PCR) to quantify
the amounts of HEV RNA. Primers for the qRT-PCR were designed using the
Beacon designer software (Premier Biosoft) to produce a 93-bp fragment within
the ORF2 gene (HEV-forward, 5-TTGGTGGCTATGCTATCT-3; HEV-re-
verse, 5-TGACATCAGTGGAGGTAA-3). The HEV RNA standards were
generated from the linearized clone pSHEV-3 using the mMessage mMachine
T7 kit (Ambion) according to the manufacturer’s protocol. Synthesized RNA
transcripts were treated with 1 l (2 U/l) of Turbo DNase (Applied Biosystems)
to remove the template DNA. The integrity of the RNA transcripts was con-
firmed by gel electrophoresis, and the RNA concentration was measured using a
NanoDrop ND-1000 instrument (Thermo Scientific). Serial 10-fold dilutions of
the in vitro-synthesized HEV RNA transcripts were used for determining the
qRT-PCR sensitivity and detection limit. The qRT-PCR was performed in a
25-l reaction mixture containing 12.5 l of SensiMix SYBR & Fluorescein (Quan-
tace Ltd.), 0.5 l of each primer (10 M), and 5 l of cDNA template. The
qRT-PCR parameters consisted of an initial PCR activation step of 95°C for 10 min
followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 59°C for 30 s, and
extension at 72°C for 15 s. Amplification and data analysis were carried out on an
iCycler thermal cycler (Bio-Rad). Samples were tested in triplicate, and a negative
control with no template was included in every set of reactions.
Nucleotide sequencing of the viruses recovered from pigs inoculated with the
HEV mutants. Samples of bile, serum, feces, and intestinal content from selected
pigs of each group inoculated with HEV mutants rF51L, rT59A, and rS390L
were amplified by RT-PCR. The PCR products of the ORF2 gene region were
subsequently sequenced to confirm that the viruses recovered from pigs origi-
nated from their respective inoculum. For the HEV mutants rF51L and rT59A,
the reverse primer 5159R1 (5-GGGCTGAACCAAAATCCTGACATC-3) was
used for cDNA synthesis, followed by a first-round PCR using the forward
5159F1 (5-ATAACATGTCTTTTGCATCGCC-3) and reverse 5159R1 prim-
ers and a second round of nested PCR using the forward 5159F2 (5-CGTGCT
TCTGCCTATGCTGC-3) and reverse 5159R2 (5-TCACGCCAAGCGGAGC
CAAGG-3) primers. For the HEV mutant rS390L, the reverse primer 390R1
(5-GAGTAGGTCGGTCTTGCTCG-3) was used for cDNA synthesis. The
first-round PCR was performed using the forward 390F1 (5-CAGCCACACG
TTTCATGAAGG-3) and reverse 390R1 primers, followed by a second round
FIG. 1. Immunofluorescence staining of a subclone of Huh7 cells transfected with similar amounts of capped full-length RNA transcripts.
(A) pSHEV-3; (B) mutant rF51L; (C) mutant rT59A; (D) mutant rS390L; (E) mock transfection. Cells were stained for HEV ORF2 protein using
chimpanzee 1313 anti-HEV immune serum.
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of nested PCR using the forward 390F2 (5-CTTGCATTTCACCGGCACGAA
C-3) and reverse 390R2 (5-GAATCACCCAGATCTATATCG-3) primers.
Structural visualization of S390L mutant capsid. All molecular graphic figures
were produced with PyMOL 0.99 molecular graphics (7; http://www.pymol.org)
on a Linux workstation. Coordinates were downloaded from Protein Data Bank
(PDB) accession number 2ZTN (chain A, residues 129 to 606) and correspond
to the X-ray structure of the genotype 3 HEV ORF2 (69). To build a backbone
model from the alignment of the wild-type and mutant (S390L) forms of ORF2,
we used the AL2TS service of the Protein Structure Prediction Center (Law-
rence Livermore National Laboratory), which converts sequence structure align-
ment into standard PDB format.
Statistical analysis. RT-PCR data (presence versus absence of HEV RNA)
were analyzed using Fisher’s exact test to simultaneously compare all the groups
as well as for the two-way comparisons of interest. P values for the two-way
comparisons after Fisher’s exact test were adjusted using Bonferroni’s procedure.
Statistical significance was set to alpha 0.05. All analyses were performed using
commercially available software (version 9.2; SAS, Cary, NC).
RESULTS
The three HEV single mutants rF51L, rT59A, and rS390L
are replication competent in Huh7 liver cells. Capped RNA
transcripts from the full-length cDNA clones of each of the
three HEV single mutants (rF51L, rT59A, and rS390L) were
transfected into Huh7 cells to determine their replication com-
petence. The RNA transcripts from the wild-type pSHEV-3
clone were also included as a positive control. The viability of
the triple mutant pSHEV-1 has been demonstrated in vitro
previously (24) and thus was not tested in this study. The
ORF2 viral antigens were detected by IFA in Huh7 cells trans-
fected with the wild-type pSHEV-3, as well as in cells trans-
fected with all three single mutants (rF51L, rT59A, and
rS390L) (Fig. 1A, B, C, and D). A positive IFA signal was seen
in the cytoplasm of Huh7 cells, whereas no detectable signal
was found in mock-transfected cells (Fig. 1E). Since ORF2
protein is synthesized from subgenomic RNAs, production of
ORF2 protein serves as a surrogate marker for viral RNA
replication. Therefore, the number of positive cells was quan-
tified by fluorescence-activated cell sorter (FACS) analysis of
transfected cells stained for HEV ORF2 protein as previously
described (56). No major differences in the production of
ORF2 protein were observed between cells transfected with
the mutants and the wild type. The mean percentage and
standard deviation of ORF2-positive cells for the wild-type
pSHEV-3 were 2.9%  2.2%, whereas the values for the single
mutants rF51L, rT59A, and rS390L and the triple mutant
pSHEV-1 were 4.2%  0.43%, 2.9%  0.40%, 1.9%  1%,
and 2.4%  2.1%, respectively.
FIG. 2. Seroconversion to anti-HEV IgG in pigs inoculated with RNA transcripts from the wild-type pSHEV-3 and HEV mutants. (A) Positive-
control pigs inoculated with the wild-type pSHEV-3; (B) pigs inoculated with the single mutant rF51L; (C) pigs inoculated with the single mutant rT59A
(one pig from this group died of septicemia at 6 days after inoculation); (D) pigs inoculated with the single mutant rS390L; (E) pigs inoculated with the
triple mutant pSHEV-1; (F) negative-control pigs inoculated with PBS. Only results for those pigs necropsied at 56 dpi are shown here. Anti-HEV IgG
was plotted as the ELISA optical density (A405), and the ELISA cutoff value was set 0.3 as previously described (15, 24, 45).
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Seroconversion to anti-HEV antibodies is delayed in SPF
pigs infected with each of the three HEV single mutants com-
pared to those infected with the wild-type pSHEV-3. Serocon-
version to IgG anti-HEV was observed in all three HEV single
mutant groups as well as in the positive-control group (Fig. 2),
indicating active HEV infection in the inoculated pigs. Pigs
inoculated with the single mutants rF51L, rT59A, and rS390L
had a 1- to 3-week-delayed seroconversion (Fig. 2B, C, and D)
compared to those infected with the wild type (Fig. 2A), while
pigs inoculated with the triple mutant pSHEV-1 failed to se-
roconvert by 56 dpi (Fig. 2E). As expected, all pigs from group
F (PBS negative control) remained seronegative throughout
the study, except for one pig at 21 to 35 dpi, which exhibited
positive optical density (OD) values (Fig. 2F). Since this pig
was negative for HEV RNA throughout the study and since
the low OD values lasted for only 3 weeks, the transient ele-
vation of OD values in this single pig is likely due to an
unexplained nonspecific response.
Pigs inoculated with HEV mutants have delayed and shorter
viremia and fecal virus shedding and lower serum viral loads
than those inoculated with wild-type pSHEV-3. Weekly serum
samples from all pigs were tested for the presence of HEV
viremia (Table 1) and serum viral RNA loads (Fig. 3) by nested
RT-PCR and quantitative real-time RT-PCR (qRT-PCR), re-
spectively. Pigs inoculated with PBS showed no detectable
HEV RNA, while those inoculated with the wild-type
pSHEV-3 had viremia starting at 14 dpi, with an average du-
ration of continuous viremia of 3.2 weeks (Table 1), and serum
viral loads ranging from 3.5 to 5.7 log10 genomic equivalent
copies (GE) per ml (Fig. 3A). Pigs inoculated with the mutant
viruses had a delayed and transient viremia that was of gener-
ally lower magnitude than that in the wild-type-virus-inocu-
lated pigs (Table 1; Fig. 3A and B).
Weekly fecal samples were collected from all pigs and tested
for the presence of HEV RNA by nested RT-PCR (Table 1).
All fecal samples collected from PBS-inoculated pigs were
negative for HEV RNA. Pigs inoculated with wild-type
pSHEV-3 or mutant rF51L shed virus in feces as early as 7 dpi,
and the average durations of continuous fecal viral shedding
were 7.8 and 5.2 weeks, respectively (Table 1). Pigs inoculated
with mutant rT59A or rS390L shed virus in feces by 21 dpi, and
the average durations of continuous fecal virus shedding were
reduced to 1.7 and 3.2 weeks, respectively (Table 1). Only one
of the pigs inoculated with the triple mutant pSHEV-1 had
detectable HEV RNA in feces at 21 and 28 dpi (Table 1).
Pigs inoculated with HEV mutants have lower viral loads in
liver tissues, bile, and intestinal content collected from each
necropsy than those inoculated with the wild-type pSHEV-3.
Pigs inoculated with PBS were negative for HEV RNA in liver,
bile, and intestinal content collected during all three different
necropsies at 21, 28, and 56 dpi. HEV RNA was detected in the
livers of 1/3, 3/3, and 2/4 wild-type-virus-inoculated pigs at 21,
28, and 56 dpi, respectively (Fig. 4A, B, and C). Pigs inoculated
with each of the single mutants (rF51L, rT59A, and rS390L)
had detectable HEV RNA in the liver, with relatively lower
viral GE titers at 28 dpi (Fig. 4B). HEV RNA was detected in
2/4 pigs inoculated with the wild type, rF51L, and pSHEV-1 at
56 dpi, though the titers of the mutant viruses were generally
lower than that of the wild-type virus (Fig. 4C).
Viral RNA was detected in bile samples collected from each
group of infected pigs at 21 dpi, with lower titers observed in
triple mutant pSHEV-1-infected pigs (Fig. 5A). Viral RNA
was consistently detected in the wild-type- and single mutant-
infected pigs at 28 dpi, with no viral RNA detected in the triple
mutant-infected pigs (Fig. 5B). At the necropsy at 56 dpi, high
levels of viral RNA were still detectable in the bile of pigs
infected with the wild-type virus, but only low levels of virus
were detectable in the bile of most pigs infected with the single
and triple mutants (Fig. 5C).
Viral RNA was detected in intestinal content collected from
TABLE 1. HEV RNA in feces and sera of specific-pathogen-free pigs intrahepatically inoculated with capped RNA transcripts from wild-type
pSHEV-3 and mutant rF51L, rT59A, rS390L, and pSHEV-1 infectious clones
Group Inoculum Sample
No. of positive pigs/no. tested at dpi: Total no. positive/
no. tested0 7 14 21 28 35 42 49 56
A pSHEV-3 Feces 0/10 3/10 8/10 10/10 7/7 4/4 4/4 4/4 4/4 10/10
Serum 0/10 0/10 1/10 2/10 6/7 2/4 2/4 2/4 1/4 7/10
B rF51L Feces 0/10 2/10 2/10 5/10 5/7 4/4 3/4 3/4 4/4 7/10
Serum 0/10 0/10 0/10 0/10 2/7 1/4 1/4 1/4 1/4 2/10
C rT59A Feces 0/10 0/9 0/9a 3/9b 5/6 3/3 0/3 0/3 0/3 8/10
Serum 0/10 0/9 0/9 0/9 0/6d 0/3 0/3 0/3 1/3 1/10
D rS390L Feces 0/10 0/10 0/10a 3/10b 7/7 4/4 4/4 0/4 0/4 8/10
Serum 0/10 0/10 0/10 1/10 1/7 3/4 0/4 0/4 0/4 5/10
E pSHEV-1 Feces 0/10 0/10 0/10a 1/10b 1/7 0/4 0/4 0/4 0/4 1/10
Serum 0/10 0/10 0/10 0/10 0/7d 0/4 0/4 2/4 1/4 2/10
F PBS Feces 0/10 0/10 0/10a 0/10b 0/7c 0/4 0/4 0/4 0/4 0/10
Serum 0/10 0/10 0/10 0/10 0/7 0/4 0/4 0/4 0/4 0/10
a Group with a statistically significant difference in the incidence of fecal virus shedding compared to the wild-type group at 14 dpi (P  0.05).
b Group with a statistically significant difference in the incidence of fecal virus shedding compared to the wild-type group at 21 dpi (P  0.05).
c Group with a statistically significant difference in the incidence of fecal virus shedding compared to the wild-type group at 28 dpi (P  0.05).
d Group with a statistically significant difference in the incidence of viremia compared to the wild-type group at 21 dpi (P  0.05).
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each group of infected pigs at 21 and 28 dpi (Fig. 6A and B).
At 56 dpi, HEV RNA was detected consistently in the intes-
tinal contents of wild-type virus-infected pigs and also in 2/4
and 1/4 of the pigs inoculated with rF51L and pSHEV-1, re-
spectively (Fig. 6C). No pigs inoculated with mutant rT59A or
rS390L had detectable viral RNA in the intestinal content at 56
dpi (Fig. 6C).
Mutations F51L and T59A are genetically stable in vivo,
whereas mutation S390L reverts to the wild-type phenotype at
later stages of infection in pigs. The viruses recovered from
pigs inoculated with the HEV mutants rF51L, rT59A, and
rS390L were partially sequenced to determine the in vivo sta-
bilities of the three single mutations introduced in the viral
capsid protein. Sequence analyses revealed that mutation F51L
was retained in the viruses recovered from feces, bile, and
intestinal contents collected at 28 and 56 dpi from pigs inocu-
lated with the mutant rF51L. Similarly, the mutation T59A was
also retained in the viruses recovered from bile and intestinal
contents collected at 28 dpi from pigs inoculated with the
mutant rT59A. However, sequence analyses of viruses recov-
ered from feces, serum, intestinal contents, and bile collected
at 21, 28, 35, and 42 dpi from six different pigs inoculated with
the single mutant rS390L revealed a mixture of both the mu-
tant and the wild-type phenotypes. The revertant population
was detected as early as 21 dpi and increasingly became the
predominant phenotype over the course of infection, with no
FIG. 3. Detection and quantification of viral RNA loads in sera of pigs inoculated with the wild-type pSHEV-3 and HEV mutants at the
different days postinoculation (dpi). (A) HEV genomic equivalent (GE) titers in sera from pigs inoculated with wild-type pSHEV-3 () and triple
mutant pSHEV-1 (). (B) HEV GE titers in sera from pigs inoculated with the single mutants rF51L (), rT59A (E), and rS390L (‚). The
numbers inside the symbol on the x axis represent the number of pigs in each group that were negative for viremia at the respective dpi. The HEV
genomic copy numbers are presented as the log10 of GE per ml of serum (y axis). The dotted line represents the limit of the sensitivity of the
qRT-PCR assay (2.90 log10 GE/ml).
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detection of the mutant rS390L in some viruses recovered from
pigs at 42 dpi.
3-D structural location of the S390L mutation in the viral
capsid. Three-dimensional (3-D) modeling of the HEV capsid
structure revealed that the S390L mutation is localized within
a putative sugar binding sequence (376ADTLLGGLPTELISS
A391) within the P1 linear domain (residues 314 to 453) (20) of
the C terminus of the capsid protein that is strictly conserved
among all four HEV genotypes. This potential sialic acid bind-
ing site maps to a helix-turn-helix motif (Fig. 7) and forms a
hidden pocket that may be responsible for binding to cell
receptors (20).
DISCUSSION
In this study, we report the identification of three amino acid
mutations in the HEV capsid protein that collectively contrib-
uted to virus attenuation in vivo. The three amino acid muta-
tions F51L, T59A, and S390L in the ORF2 capsid were iden-
tified in the genome of a genotype 3 HEV infectious clone
(pSHEV-1) from a previous study (24). ORF2 partially over-
laps ORF3; however, the three mutations in the ORF2 capsid
do not change the amino acid sequence of the ORF3 protein.
In this study, three HEV mutants with a single amino acid
change (rF51L, rT59A, and rS390L) were constructed, and all
were shown to be replication competent and viable after trans-
fection into a subclone of Huh7 human liver cells. No major
difference was observed in the production of HEV ORF2 pro-
tein in cells transfected with the wild type and the mutants. The
pig model system has been used to understand various aspects
of HEV replication, pathogenesis, and cross-species infection
(16, 44, 45, 51, 66). Due to limited resources and restricted
procedures for nonhuman primates, it is not possible to use a
large number of nonhuman primates for HEV pathogenicity
studies. Therefore, we conducted a pathogenicity study of
these three single mutants using a large number of SPF pigs in
each group (n  10). We showed that in the positive-control
pigs inoculated with the wild-type pSHEV-3, fecal virus shed-
ding preceded the onset of viremia, and the patterns of viremia
and fecal virus shedding in pSHEV-3-infected pigs were con-
sistent with those observed in previous studies (21, 43). An IgG
anti-HEV response was detected 1 to 2 weeks after the onset
of viremia and remained detectable until the end of the 8-week
study. Peak viral loads in serum, liver, bile, and intestinal
content were detected at 28 dpi, with a temporal decrease of
viral genome titers concurrent with the increase of HEV anti-
bodies. In pigs inoculated with the wild-type pSHEV-3, the
virus was not fully cleared by the immune response by 56 dpi,
as evidenced by continuous fecal shedding in all pigs and the
presence of high viral loads in liver, bile, and intestinal content
at the end of the 8-week study.
In a previous pilot study with only two pigs (24), we dem-
FIG. 4. Detection and quantification of viral RNA loads in livers of pigs inoculated with the wild-type pSHEV-3 and HEV mutants. HEV GE
titers were determined from samples harvested at necropsies on days 21 (A), 28 (B), and 56 (C). Data are shown as log10 of GE per mg of liver.
The dotted line represents the limit of the sensitivity of the qRT-PCR assay (1.53 log10 GE/mg).
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onstrated the viability of the triple mutant pSHEV-1 in vivo. In
this study, we confirmed that the triple mutant pSHEV-1 is
infectious in vivo, as HEV RNA was detected in serum and
fecal samples as well as in liver, bile, and intestinal contents of
inoculated pigs. However, the pSHEV-1 with the triple muta-
tions in the capsid protein was clearly attenuated compared to
the wild-type pSHEV-3, as fewer pigs were viremic or shed
virus in feces. For those pigs that did have detectable viremia
and fecal virus shedding, viremia was delayed by 5 weeks,
serum viral loads were drastically lower, and fecal virus shed-
ding was also delayed and had a shorter duration. In addition,
none of the pigs inoculated with pSHEV-1 seroconverted by 56
dpi, which is consistent with our pilot study, in which the two
pigs inoculated with pSHEV-1 did not seroconvert until 63 dpi
(24).
To determine which of the three amino acid mutations were
responsible for the observed attenuation of the pSHEV-1 virus
in pigs, we constructed three HEV single mutants (rF51L,
rT59A, and rS390L), each containing a single amino acid mu-
tation, and compared the in vivo pathogenicities of the three
HEV single mutants in pigs to those of each other and the
wild-type pSHEV-3. For the rF51L mutant, seroconversion
and viremia were delayed 2 to 3 weeks compared to those with
the wild-type pSHEV-3, and the incidence of viremia was
lower. However, the serum viral loads were similar for the
rF51L mutant and the wild-type pSHEV-3, and like the wild-
type pSHEV-3, the mutant rF51L virus was also not fully
cleared in pigs at the end of the 8-week study, as evidenced by
viremia and fecal virus shedding at 56 dpi. Inefficient viral
clearance for the rF51L mutant-inoculated pigs was also ob-
served in liver, bile, and intestinal content, although viral loads
were lower than those in the pigs inoculated with wild-type
pSHEV-3. The results suggest that the F51L mutation in the
capsid protein only partially contributes to virus attenuation.
For the rT59A mutant, seroconversion in pigs was delayed 1 to
3 weeks. Viral RNA was detected in the liver, bile, intestinal
content, and fecal materials at 21 to 35 dpi, but viremia was not
detected in any of the rT59A-inoculated pigs until 56 dpi. Unlike
the wild-type pSHEV-3 and mutant rF51L, the mutant rT59A
virus was completely cleared from feces, liver, bile, and intestinal
content at 56 dpi. Also, the viral loads in bile, liver, and intestinal
contents collected at the necropsy at 28 dpi were lower than those
of the wild-type pSHEV-3. Therefore, the T59A mutation in the
capsid is important for virus attenuation in pigs.
For mutant rS390L, the inoculated pigs had a more drastic
delay in seroconversion (3 to 4 weeks later than seroconversion
with the wild-type pSHEV-3). Similarly, viremia and fecal virus
shedding were also delayed compared to those with the wild-
type pSHEV-3 virus. Among the three single mutants, mutant
rS390L had the lowest viral loads in liver and bile of pigs
necropsied at 21, 28, and 56 dpi. Pigs infected with mutant
rS390L completely cleared the virus from serum and feces by
FIG. 5. Detection and quantification of viral RNA loads in bile samples from pigs inoculated with the wild-type pSHEV-3 and HEV mutants.
HEV GE titers were determined from samples harvested at necropsies on days 21 (A), 28 (B), and 56 (C). Data are shown as log10 of GE per ml
of bile. The dotted line represents the limit of the sensitivity of the qRT-PCR assay (2.90 log10 GE/ml).
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42 and 49 dpi, respectively, and the liver, bile, and intestinal
content collected at the end of the 8-week study had no de-
tectable virus. Therefore, the results indicate that the S390L
mutation in the HEV capsid protein is critical for virus atten-
uation in pigs.
Mutations F51L and T59A are both located in the N-termi-
nal region of the HEV capsid protein, which contains a signal
peptide (aa 1 to 22) involved in the translocation of the protein
across the endoplasmic reticulum membrane (72), followed by
an arginine-rich domain (aa 23 to 111) that may be involved in
RNA encapsidation (59, 72). Therefore, it is possible that the
F51L and T59A mutations contribute to virus attenuation by
causing a defect in viral genomic RNA packaging, thus result-
ing in a lower level of infectious virus production in vivo. The
observed reduction of viral loads in bile, liver, and intestinal
content and the lower incidence of viremia and fecal virus
shedding with both mutants are consistent with this explana-
tion. The T59A mutation appears to have a greater impact on
viral replication than the F51L mutation, as no viremia was
detected and viral loads and fecal virus shedding were greatly
reduced. It is possible that the polarity change of the mutation
T59A more drastically affects the function of the N-terminal
domain. This would explain the observed difference in the level
of attenuation between the two mutants, since the F51L mu-
tation did not result in a polarity change.
The C terminus of the HEV capsid protein is the major
structural domain responsible for virion assembly, immunoge-
nicity, and host cell receptor binding (23, 30, 34, 39, 55). Con-
structs (aa 112 to 607) lacking the N terminus have been shown
to self-assemble into virus-like particles (VLPs) in a baculovi-
rus expression system (34), and a truncated C-terminal pep-
tide, p239 (aa 368 to 606), of the HEV capsid protein induced
protective immunity against HEV challenge in nonhuman pri-
mates (32). This p239 peptide has also been reported to bind
and penetrate cell lines that are susceptible to HEV, suggest-
ing the presence of HEV receptor binding sites in this C-ter-
minal region (23). The crystal structure of genotype 3 HEV
VLPs assembled from a truncated version of the ORF2 capsid
protein (residues 129 to 606) was determined at 3.5-Å resolu-
tion (69). Three structural domains have been defined within
ORF2: S (residues 118 to 313), P1 (residues 314 to 453), and
P2 (residues 454 to 606). P1 and S are closely associated and
exposed on the surface of the capsid around the icosahedral
3-fold axis, and P1 and P2 are connected through a flexible
proline-rich hinge that spans residues 445 to 467 (69) (Fig.
7A). The S domain forms a continuous capsid shell, whereas
P2 is highly exposed and is largely responsible for antigenicity
determination and virus neutralization (20, 69). Although
there is no direct evidence regarding glycosylation of the HEV
VLP capsid, consensus sites have been located within the S
(Asn137-Leu-Ser and Asn130-Leu-Thr) and P2 (Asn562-Thr-
Thr) domains (69, 72), with evidence pointing toward a direct
FIG. 6. Detection and quantification of viral RNA loads in intestinal contents of pigs inoculated with the wild-type pSHEV-3 or HEV mutants.
HEV GE titers were determined from samples harvested at necropsies on days 21 (A), 28 (B), and 56 (C). Data are shown as log10 of GE per ml
of intestinal content suspension. The dotted line represents the limit of the sensitivity of the qRT-PCR assay (2.90 log10 GE/ml).
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role of Asn137 and Asn130 in virus infectivity and virion as-
sembly (49). Structural analysis of the P1 domain, an antipar-
allel -barrel composed of six -strands and four short helices
(20, 69) (Fig. 7B), reveals the presence of a putative sugar
binding site (376ADTLLGGLPTELISSA391) that resembles
the one site identified in the endosialidase of the K1F phage
(PDB accession no. 1VOE), which maps within a helix-turn-
helix motif of P1 (Fig. 7B and C) and may be responsible for
binding to cell receptors (20). Amino acid position 390, which
is conserved among all four major genotypes of mammalian
HEV, is localized within this potential sialic acid binding site in
the P1 linear domain. Although the HEV dimer shows a cross-
ing topology of the C-terminal P2 domain versus the P1 and S
domains, stability of the dimer is ensured by the interaction
between the P2 domain of one monomer and the P2 and P1
domains of the other (69), with the sugar binding site exposed
in the opposite interface of P1 (Fig. 7D). Interestingly, He et
al. showed that various monoclonal antibodies directed against
conformational and linear epitopes in P1 and P2 were able to
block the binding of a truncated peptide (p239, residues 368 to
606) of ORF2, which occurs as 23-nm particles, to various cell
lines (23). Largely based on selective blocking by monoclonal
antibodies, He et al. concluded that the region comprising
residues 368 to 606 should contain at least two distinct sites,
located separately in the monomeric and dimeric domains,
involved in binding. Remarkably, two of the monoclonal anti-
bodies against linear epitopes in P1 (residues 423 to 438 [an-
tibody 12A10] and 423 to 443 [antibody Ab 16D7]) that neu-
tralize the binding of p239 particles to Huh7 cells map on the
same interface as Ser390 (23) (Fig. 7D), suggesting a potential
site of contact within that region. Therefore, the mutation from
a polar residue (Ser) to a nonpolar residue (Leu) at position
FIG. 7. Structural location of S390 within the capsid protein of HEV. (A) Crystal structure of the truncated HEV capsid protein (residues 129
to 606) (PDB accession no. 2ZTN) (69). Domains are indicated as follow: shell (S) (residues 118 to 313) in yellow and subdomains P1 (residues
314 to 453) in green and P2 (residues 454 to 606) in cyan of the protruding (P) domain. (B) Ribbon diagram of the ternary P1 domain, showing
the putative glycosylation site (376ADTLLGGLPTELISSA391, in orange). The S390 residue is shown in magenta and maps within a helix-turn-helix
motif. (C) Schematic presenting the residues within a 4-Å distance from S390. Those residues that are part of the putative glycosylation site are
in orange (386ELISSA391). Residues in green are part of the loop and -sheet and comprise residues 392GGQLF396. The side chain of an additional
residue, T414, located within a 4-Å distance is also indicated. (D) Surface map showing the location of residue S390 and linear epitopes of the
12A10 and 16D7 (purple) and 15B2 (yellow) monoclonal antibodies (23). Images were generated using PyMOL (7).
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390 may prevent the rS390L mutant from efficiently interacting
with the host cell receptor. Crystal structure studies have
shown that this putative sugar binding motif may be responsi-
ble for destabilization of HEV capsid trimers during uncoating
(20). Defects in receptor binding and uncoating would both
result in a lower level of virus replication in the host and thus
would explain why mutant rS390L appeared to contribute the
most to virus attenuation among the three single HEV mu-
tants.
It has been well documented that one or more amino acid
changes in capsid or envelope proteins can contribute to the
attenuation phenotype of viruses (8, 50, 52, 64, 65). Single
point mutations in the capsids of poliovirus (65), murine no-
rovirus (4), infectious bursal disease virus (64), and adeno-
associated viruses (67) have all been demonstrated to have
significant effects on both in vitro and in vivo growth charac-
teristics of the viruses. Reversion of an attenuated phenotype
to a pathogenic wild type has also been reported for many
animal viruses, such as poliovirus (35), porcine reproductive
and respiratory syndrome virus (48), and infectious bursal dis-
ease virus (54). In the current study, the F51L and T59A
mutants are genetically stable in pigs, as the viruses recovered
from the inoculated pigs over the course of infection all re-
tained these two mutations. However, in pigs inoculated with
the mutant rS390L, a mixture of both the wild-type and atten-
uated mutant phenotype viruses was recovered from feces,
serum, bile, and intestinal content as early as 21 dpi. As the
course of infection progressed, the wild-type phenotype virus
population increasingly became predominant, and by 42 dpi,
the rS390L mutant virus was no longer detectable in some
infected pigs. The fact that the mutant rS390L had mutated
back to the wild-type sequence at later stages of virus infec-
tion indicates a strong biological importance of this amino
acid residue in the functionality of the HEV capsid protein.
It took at least 21 days of replication in pigs before the
wild-type phenotype population reached a level similar to
that of the mutant virus population in infected pigs (data not
shown). The lower populations of the wild-type virus, during
the first few weeks of infection contribute to the observed
attenuation in pigs inoculated with the mutant rS390L.
However, in our previous pilot study with only two pigs (24),
the three nonsilent mutations F51L, T59A, and S390L in the
capsid gene of the triple mutant pSHEV-1 were retained in
the genome for up to 70 dpi. Therefore, reversion to the
wild-type phenotype appears to be greater for the single
mutant (such as rS390L) than the triple mutant pSHEV-1,
since only one nucleotide change is required to restore the
original sequence. All three mutants (F51L, T59A, and
S390L) are created by a single nucleotide change, and there-
fore it will be interesting to see in a future animal study if
the attenuation phenotype of mutant S390L can be stabi-
lized by changing two nucleotides of codon 390.
Taken together, the results from this study indicated that the
three amino acid mutations in the HEV capsid protein collec-
tively contribute to virus attenuation. The F51L mutation re-
sulted in only partial attenuation, whereas the T59A and
S390L mutations attenuated the virus more drastically. The
significant attenuation for the triple mutant pSHEV-1 was
likely due to the additive effect of the three individual amino
acid mutations. Additional phenotypic markers of HEV atten-
uation need to be identified and characterized for the devel-
opment of a modified live-attenuated vaccine when HEV can
be efficiently propagated in vitro.
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